- Home
- PRLD vs HBIO Comparison
PRLD vs HBIO Comparison
Compare PRLD & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- HBIO
- Stock Information
- Founded
- PRLD 2016
- HBIO 1901
- Country
- PRLD United States
- HBIO United States
- Employees
- PRLD N/A
- HBIO N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- HBIO Biotechnology: Laboratory Analytical Instruments
- Sector
- PRLD Health Care
- HBIO Industrials
- Exchange
- PRLD Nasdaq
- HBIO Nasdaq
- Market Cap
- PRLD 73.7M
- HBIO 61.2M
- IPO Year
- PRLD 2020
- HBIO 2000
- Fundamental
- Price
- PRLD $0.82
- HBIO $0.57
- Analyst Decision
- PRLD Strong Buy
- HBIO Buy
- Analyst Count
- PRLD 2
- HBIO 1
- Target Price
- PRLD $4.50
- HBIO $4.50
- AVG Volume (30 Days)
- PRLD 201.7K
- HBIO 377.6K
- Earning Date
- PRLD 03-10-2025
- HBIO 03-12-2025
- Dividend Yield
- PRLD N/A
- HBIO N/A
- EPS Growth
- PRLD N/A
- HBIO N/A
- EPS
- PRLD N/A
- HBIO N/A
- Revenue
- PRLD $7,000,000.00
- HBIO $94,135,000.00
- Revenue This Year
- PRLD N/A
- HBIO N/A
- Revenue Next Year
- PRLD N/A
- HBIO $7.97
- P/E Ratio
- PRLD N/A
- HBIO N/A
- Revenue Growth
- PRLD N/A
- HBIO N/A
- 52 Week Low
- PRLD $0.63
- HBIO $0.56
- 52 Week High
- PRLD $6.80
- HBIO $4.70
- Technical
- Relative Strength Index (RSI)
- PRLD 56.29
- HBIO 22.38
- Support Level
- PRLD $0.71
- HBIO $0.56
- Resistance Level
- PRLD $0.76
- HBIO $0.63
- Average True Range (ATR)
- PRLD 0.07
- HBIO 0.06
- MACD
- PRLD 0.02
- HBIO 0.02
- Stochastic Oscillator
- PRLD 87.50
- HBIO 3.00
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About HBIO Harvard Bioscience Inc.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab.. The majority of its revenue comes from the United States.